JPH0533230B2 - - Google Patents

Info

Publication number
JPH0533230B2
JPH0533230B2 JP59166911A JP16691184A JPH0533230B2 JP H0533230 B2 JPH0533230 B2 JP H0533230B2 JP 59166911 A JP59166911 A JP 59166911A JP 16691184 A JP16691184 A JP 16691184A JP H0533230 B2 JPH0533230 B2 JP H0533230B2
Authority
JP
Japan
Prior art keywords
water
added
fnmr
hours
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP59166911A
Other languages
Japanese (ja)
Other versions
JPS6144890A (en
Inventor
Tadahiko Tsushima
Kenji Kawada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Priority to JP16691184A priority Critical patent/JPS6144890A/en
Publication of JPS6144890A publication Critical patent/JPS6144890A/en
Publication of JPH0533230B2 publication Critical patent/JPH0533230B2/ja
Granted legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

【発明の詳細な説明】[Detailed description of the invention]

A 発明の目的 a 産業上の利用分野 本発明は抗ガン剤として有用な含フツ素メトト
レキサート誘導体に関する。 b 従来の技術 ジヒドロ葉酸還元酵素阻害作用を有するメトト
レキサートは白血病、絨毛性腫瘍などの各種の悪
性腫瘍に対する治療剤として使用されている(米
国特許第4057578号)。 c 発明が解決しようとする問題点 上記メトトレキサートはかなりの毒性を有して
いるため各種腫瘍に対する大量投与には適さな
い。そこで大量投与に適する低毒性の抗ガン剤の
開発が望まれる。 B 発明の構成 本発明は一般式 (式中、R1は水素またはフツ素、R2は水素ま
たはジフルオロメチルをそれぞれ表わすが、R1
とR2が同時に水素である場合を除く。)で示され
る化合物またはその塩に関し、低毒性抗ガン剤を
提供することを目的とする。 上記化合物()は一般式 [式中、A1およびA2はエステル残基(例えば、
C1−C5アルキル(メチル、エチル、n−プロピ
ル、イソプロピル、n−ブチル、イソブチル、
sec−ブチル、tert−ブチル、n−ペンチル、イ
ソペンチル、sec−ペンチル、neo−ペンチル、
tert−ペンチルなど)、フエニルC1−C5アルキル
(但しC1〜C5アルキルは前記と同意義を有する。)
またはニトロ、メトキシなどの置換基を有するフ
エニルなど)を表わし、R1およびR2は前記と同
意義を有する。]で示される化合物に6−ハロメ
チル−2,4−ジアミノプテリジン()を反応
させたのち、得られる一般式 [式中、A1,A2,R1およびR2は前記と同意義
を有する。] で示される化合物を加水分解に付して得られる。 上記の製造法を下記に図示する: [式中、Halはハロゲン(例えば、塩素、臭
素、ヨウ素など)を表わし、A1,A2,R1および
R2は前記と同意義を有する。] 上記製造法について以下に詳しく説明する。 原料物質()と6−ハロメチル−2,4−ジ
アミノブテリジン()との反応は、適当な溶媒
中15〜120℃の温度で実施すればよい。溶媒とし
てはジメチルホルムアミド、ジメチルアセトアミ
ド、ジメチルスルホキシド、クロロホルム、ヘキ
サメチルリン酸トリアミド、またはそれらの混合
溶媒などが例示される。反応を促進させるため、
適当な塩基(例えば、トリエチルアミン、ピリジ
ン、ジメチルアニリンなど)を添加してもよい。 次に、中間体エステル()の加水分解は常法
により実施されるが、一般には適当な溶媒中水お
よび無機塩基(例えば、水酸化アルカリ、炭酸水
素アルカリ、炭酸アルカリ)と15〜100℃、好ま
しくは室温(15〜25℃)で処理すればよい。溶媒
としてはメタノール、エタノール、イソプロパノ
ールなどのアルコール類、アセトン、ジオキサ
ン、ジメチルスルホキシドなどの水と混合し得る
溶媒、または、それらの混合物が挙げられる。 原料物質()はグルタルミン酸類()*1)
ら容易に導かれる。 *1 グルタミン酸類()の合成 γ−クルオログルタミン酸はCan.J.
Chem.40.1571(1962)に記載と同様の方法で得ら
れる。 [式中、Xはハロゲン(例えば、塩素、臭素な
ど)、Zはアミノ保護基(例えば、カルボベンゾ
キシ、t−ブトキシカルボニル、トリチルなど)
を表わし、A1,A2,R1およびR2は前記と同意義
を有する。] 目的物質()は置換基R1,R2に応じた光学
異性体として生成するが、これらは容易に常法に
より分割することができ、いずれも本発明の対象
となる。 目的物質()はメトトレキサートよりも低い
毒性を示し、なお制ガン作用も優れているので、
抗ガン剤として有用である。 本発明目的物質()はヒトまたは動物に経口
または非経口的に投与し得る。例えば、化合物
()は錠剤、顆粒剤、散剤、カプセル剤、液剤
などとして経口的に、また注射剤などとして非経
口的に投与される。これらの製剤は賦形剤、結合
剤、崩壊剤、滑沢剤、安定剤、矯味矯臭剤などの
添加剤を用いて周知の方法に従つて製造される。 目的物質()を成人の腫瘍治療に使用する場
合、1〜500mgを1日1回または数回に分けて経
口的または非経口的に投与すればよいが、患者の
性別・年齢・病状などに適合した量を投与するの
が好ましい。 以下に本発明の実施の態様を示す。 実施例 1 1.15gをジメチルアセトアミド11mlに溶
かした溶液に6−ブロモメチル−2,4−ジア
ミノプテリジン臭化水素酸塩・イソプロパノー
ル付加物*2)1.19gを加え、50〜55℃で9時間攪
拌する。反応後を室温で一夜放置し、水110ml
を加え、氷冷下に2時間攪拌する。析出する沈
殿を濾取し、クロロホルム400mlに溶解する。
クロロホルム層を0.3Nアンモニア水400ml、次
いで水で洗浄し、無水芒硝で乾燥し、溶媒を留
去する。残渣をローバーカラム(Lobar
column)によるシリカゲルクロマトグラフイ
ーに付し、クロロホルム:メタノール(100:
5v/v)で溶出する。溶出液を濃縮し、ジイ
ソプロピルN−[4[[(2,4−ジアミノ−6−
プテリジニル)メチル]メチルアミノ]ベンゾ
イル]−γ−フルオログルタメート 1.36gを
得る。収率79.1%、融点168−169℃(アセトニ
トリルから再結晶)。 質量スペトクルm/z 556(M+),536(M+
HF),449(M+−CO2i−Pr−HF),134
(CH3NH−C6H4CO) 19FNMR(DMSO−d6)δ(C6F6)−30.42
〜−26.92(m,1F) b 上記 1.36gを熱エタノール40mlに溶解し
た溶液に1N水酸化ナトリウム水溶液8mlを室
温で加え、室温下に24時間攪拌する。反応液に
水32mlを加えて析出した沈殿を溶解したのち、
エタノールを留去する。残渣に水を加えて全量
を48mlとしたのち、1N塩酸でPH7とする。氷
冷後、混合液を濾過し、濾液を1N塩酸でPH3.1
〜3.2とする。冷蔵庫中で一夜放置後、沈殿を
濾取し、水30mlに懸濁し、1N水酸化ナトリウ
ム水溶液でPH8−9とし、さらに1N塩酸でPH
5.5とし、濾過する。濾液を1N塩酸でPH3.1と
し、冷蔵庫中で一夜放置する。析出する沈殿を
濾取し、N[4−[[(2,4−ジアミノ−6−プ
テリジニル)メチル]メチルアミノ]ベンゾイ
ル]−γ−フルオログルタミン酸1.02gを得
る。収率83.6%、融点:220〜250℃で徐々に分
解。 元素分析 C20H21O5N8F・2.5H2Oとして 計算値(%):C,46.41;H,5.06;N,21.66;
F,3.67 実験値(%):C,46.21;H,5.04;N,21.47;
F,3.47 19FNMR(DMSO−d6)δ(C6F6)−26.00
〜−22.00(m,1F) *1 6−ブロモメチル−2,4−ジアミノプテ
リジンの合成はJ.Org.Chem.422081977に記載
の方法で行なつた。 実施例 2 318mgをジメチルアセトアミド3.2mlに溶
解した溶液に6−ブロモメチル−2,4−ジア
ミノプテリジン臭化水素酸塩・イソプロパKー
ル付加物351mgを加え、50〜55℃で8時間攪拌
する。反応液を実施例1(a)と同様に処理し、ジ
メチルN−[4−[[(2,4−ジアミノ−6−プ
テリジニル)メチル]メチルアミノ]ベンゾイ
ル]−α−ジフルオロメチルグルタメート
422mgを得る。収率87.9%、融点176〜177.5℃
(アセトニトリルから再結晶)。 質量スペトクルm/z 532(M+),500(M+
N2H4),134(CH3NHC6H4CO) 19FNMR(DMSO−d6)δ(C6F6)33.67〜
35.67(4 linbes,2F) b 331mgをエタノール11mlに懸濁した液に
1N水酸化ナトリウム2.21mlを加え、室温下に
24時間攪拌し、冷蔵庫中で一夜放置する。析出
する沈殿を濾取し、水5.1mlに溶解し、濾過す
る。濾液を1N塩酸でPH4とし、氷冷して析出
する沈殿を濾取し、N−[4−[[(2,4−ジア
ミノ−6−プテリジニル)メチル]メチルアミ
ノ]ベンゾイル]−α−ジフルオロメチルグル
タミン酸 260mgを得る。収率80.0%、融点
205〜207℃(分解)。 元素分析 C21H22O5N8F2・1.5H2Oとして 計算値(%):C,47.46;H,4.74;N,21.09;
F,7.15 実験値(%):C,47.43;H,4.77;N,21.02;
F,7.13 19FNMR(DMSO−d5)δ(C6F6)35.33
(d,2F,J=56.5Hz) 参考例 1 (Cbz:カルボベンゾキシ;i−pr:イソプロ
ピル) a γ−フルオログルタミン酸 4gとイソプ
ロパノール100mlの混合物に塩化チオニル24.6
mlを加え、15時間加熱還流する。冷後、反応液
から溶媒を留去し、さらにイソプロパノールを
加えたのち、濃縮すると、ジイソプロピルγ−
フルオログルタメート塩酸塩 6.91gを得る。
これをエーテル−石油エーテルから結晶化し、
さらにアセトン−エーテルから再結晶すると、
融点140〜143℃の結晶となる。 19FNMR(アセトン−d6)δ(C6F6)−28.00
〜−25.67(m,1F) b 上記 6.91gとジメトキシエタン88mlとか
らなる懸濁液にN−カルボベンゾキシ−N−メ
チル−4−アミノベンゾイルクロリド8.82gを
加え、氷冷下トリエチルアミン8.44mlを滴下
し、そのまま2時間攪拌する。反応後に酢酸エ
チルを加え、希塩酸、水、希炭酸水素ナトリウ
ム水溶液および水で順次洗浄し、無水芒硝で乾
燥し、濃縮する。残渣をローバーカラムによる
シリカゲルクロマトグラフイーに付し、ベンゼ
ン:酢酸エチル(5:1v/v)で溶出する。
溶出液を濃縮し、ジイソプロピルN−カルボベ
ンゾキシ−N−メチル−4−アミノベンゾイル
−γ−フルオログルタメート 11.19gを得
る。収率89.5%、融点88〜89℃(エーテル−石
油エーテルから再結晶)。 19FNMR(CDCl3)δ(C6F6)−30.00〜−
27.58(m,1F) c 上記 5.15gに30%臭化水素−酢酸26mlを
加え、室温下に4時間攪拌する。反応液にエー
テル260mlを加え、冷時傾斜してエーテル溶液
を除く。残りの油状物をエーテルで洗浄し、塩
化メチレンに溶解する。塩化メチレン溶液を
1N炭酸水素カリウム水溶液および水で順次洗
浄し、無水芒硝で乾燥し、濃縮すると、油状物
としてジイソプロピルN−メチル−4−アミノ
ベンゾイル−γ−フルオログルタメート
3.40gを得る。収率89.2%。これをローバーカ
ラムによるシリカゲルクロマトグラフイーに付
し、ベンゼン:酢酸エチル(3:1v/v)で
溶出する。溶出液を濃縮し、残渣を酢酸エチル
−石油エーテルから再結晶すると、融点101〜
104℃の結晶となる。 19FNMR(アセトン−d6)δ(C6F6)−29.00
〜−26.17(m,1F) 参考例 2 a α−ジフルオロメチルグルタミン酸・0.5水
和物10 1.23gをメタノール35mlに溶解し、−10
℃に冷却し、これにトリフルオロメタンスルホ
ン酸0.58mlおよび塩化チオニル6.07mlを加え、
50〜60℃で一夜加熱攪拌する。冷後、反応液か
ら溶媒を留去し、さらに残渣にメタノールを加
え、再び濃縮すると、ジメチルα−ジフルオロ
メチルグルタメート・トリフルオロメタンスル
ホン酸塩、11 2.24gを油状物として得る。 19FNMR(D2O)δ(C6F6)34.47(dd,1F,
JFF=283.9Hz,JHF=52.9Hz),39.60(dd,1F,
JFF=283.9Hz,JHF=51.3Hz) b 11 2.24gとジメトキシエタン7.4mlの混合物
にN−カルボベンゾキシ−N−メチル−4−ア
ミノベンゾイルクロリド9.06gを加え、さらに
氷冷下トリエチルアミン5.83mlを滴下する。混
合物を氷冷下30分間攪拌後、さらに室温下に
1.5時間攪拌する。反応液を参考例1(b)と同様
に処理し、油状物としてジメチルN−カルボベ
ンゾキシ−N−メチル−4−アミノベンゾイル
−α−ジフルオロメチルグルタメート12
1.86gを得る。 質量スペクトルm/z 492(M+),448(M+
C3H8),268(
A. Object of the Invention a. Industrial Application Field The present invention relates to a fluorine-containing methotrexate derivative useful as an anticancer agent. b. Prior Art Methotrexate, which has a dihydrofolate reductase inhibitory effect, is used as a therapeutic agent for various malignant tumors such as leukemia and chorionic tumors (US Pat. No. 4,057,578). c Problems to be Solved by the Invention The above-mentioned methotrexate has considerable toxicity and is therefore not suitable for large-scale administration to various tumors. Therefore, the development of low-toxicity anticancer drugs suitable for large-scale administration is desired. B. Structure of the invention The present invention is based on the general formula (In the formula, R 1 represents hydrogen or fluorine, and R 2 represents hydrogen or difluoromethyl, respectively .
and R 2 are hydrogen at the same time. ) or a salt thereof, the purpose of which is to provide a low toxicity anticancer agent. The above compound () has the general formula [where A 1 and A 2 are ester residues (e.g.
C1 - C5 alkyl (methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl,
sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, neo-pentyl,
tert-pentyl, etc.), phenylC 1 -C 5 alkyl (C 1 -C 5 alkyl has the same meaning as above.)
or phenyl having a substituent such as nitro or methoxy), and R 1 and R 2 have the same meanings as above. The general formula obtained by reacting the compound represented by ] with 6-halomethyl-2,4-diaminopteridine () [In the formula, A 1 , A 2 , R 1 and R 2 have the same meanings as above. ] It is obtained by subjecting the compound represented by these to hydrolysis. The above manufacturing method is illustrated below: [In the formula, Hal represents a halogen (e.g. chlorine, bromine, iodine, etc.), and A 1 , A 2 , R 1 and
R 2 has the same meaning as above. ] The above manufacturing method will be explained in detail below. The reaction between the raw material () and 6-halomethyl-2,4-diaminobuteridine () may be carried out in a suitable solvent at a temperature of 15 to 120°C. Examples of the solvent include dimethylformamide, dimethylacetamide, dimethylsulfoxide, chloroform, hexamethylphosphoric triamide, and a mixed solvent thereof. To accelerate the reaction,
A suitable base (eg triethylamine, pyridine, dimethylaniline, etc.) may be added. Next, hydrolysis of the intermediate ester () is carried out by a conventional method, but generally, water and an inorganic base (e.g., alkali hydroxide, alkali hydrogen carbonate, alkali carbonate) are added in a suitable solvent at 15 to 100°C. Preferably, the treatment may be carried out at room temperature (15 to 25°C). Examples of the solvent include alcohols such as methanol, ethanol, and isopropanol, solvents that are miscible with water such as acetone, dioxane, and dimethyl sulfoxide, and mixtures thereof. The raw material () can be easily derived from glutaric acids ( *1) . *1 Synthesis of glutamic acids () γ-chloroglutamic acid is produced by Can.J.
Obtained by a method similar to that described in Chem. 40.1571 (1962). [wherein,
, and A 1 , A 2 , R 1 and R 2 have the same meanings as above. ] The target substance ( ) is produced as optical isomers depending on the substituents R 1 and R 2 , but these can be easily resolved by conventional methods, and both are subject to the present invention. The target substance () exhibits lower toxicity than methotrexate and also has excellent anticancer effects.
It is useful as an anti-cancer agent. The object substance of the present invention () can be administered orally or parenterally to humans or animals. For example, the compound () can be administered orally in the form of tablets, granules, powders, capsules, liquids, etc., or parenterally as injections, etc. These preparations are manufactured according to well-known methods using additives such as excipients, binders, disintegrants, lubricants, stabilizers, and flavoring agents. When using the target substance () for tumor treatment in adults, it is sufficient to administer 1 to 500 mg orally or parenterally once a day or in several divided doses, but depending on the patient's gender, age, medical condition, etc. Preferably, a compatible amount is administered. Embodiments of the present invention are shown below. Example 1 Add 1.19 g of 6 -bromomethyl-2,4-diaminopteridine hydrobromide/isopropanol adduct *2) to a solution of 1.15 g of a1 dissolved in 11 ml of dimethylacetamide, and stir at 50 to 55°C for 9 hours. After the reaction, leave it at room temperature overnight and add 110ml of water.
and stir for 2 hours under ice-cooling. Collect the precipitate by filtration and dissolve it in 400 ml of chloroform.
The chloroform layer is washed with 400 ml of 0.3N aqueous ammonia and then with water, dried over anhydrous sodium sulfate, and the solvent is distilled off. The residue is transferred to a Lobar column (Lobar column).
silica gel chromatography using chloroform:methanol (100:
Elute at 5v/v). The eluate was concentrated and diisopropyl N-[4[[(2,4-diamino-6-
1.36 g of pteridinyl)methyl]methylamino]benzoyl]-γ-fluoroglutamate 2 are obtained. Yield 79.1%, melting point 168-169°C (recrystallized from acetonitrile). Mass spectrum m/z 556 (M + ), 536 (M +
HF), 449 (M + −CO 2 i−Pr−HF), 134
( CH3NHC6H4CO ) 19 FNMR (DMSO− d6 )δ( C6F6 ) −30.42
~-26.92 (m, 1F) b To a solution of 1.36 g of the above 2 dissolved in 40 ml of hot ethanol, 8 ml of 1N aqueous sodium hydroxide solution is added at room temperature, and the mixture is stirred at room temperature for 24 hours. After adding 32 ml of water to the reaction solution and dissolving the precipitate,
Distill ethanol away. Add water to the residue to bring the total volume to 48 ml, and then adjust the pH to 7 with 1N hydrochloric acid. After cooling on ice, filter the mixture and adjust the filtrate to pH3.1 with 1N hydrochloric acid.
~3.2. After standing overnight in the refrigerator, the precipitate was collected by filtration, suspended in 30 ml of water, adjusted to pH 8-9 with 1N aqueous sodium hydroxide solution, and further adjusted to pH 8-9 with 1N hydrochloric acid.
5.5 and filter. Adjust the filtrate to pH 3.1 with 1N hydrochloric acid and leave it in the refrigerator overnight. The deposited precipitate was collected by filtration to obtain 1.02 g of N[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-γ-fluoroglutamic acid 3 . Yield 83.6%, melting point: gradual decomposition at 220-250℃. Elemental analysis Calculated value (%) as C 20 H 21 O 5 N 8 F・2.5H 2 O: C, 46.41; H, 5.06; N, 21.66;
F, 3.67 Experimental value (%): C, 46.21; H, 5.04; N, 21.47;
F , 3.47 19 FNMR(DMSO− d6 )δ( C6F6 )−26.00
~-22.00 (m, 1F) *1 6-bromomethyl-2,4-diaminopteridine was synthesized by the method described in J.Org.Chem.422081977. Example 2 351 mg of 6 -bromomethyl-2,4-diaminopteridine hydrobromide/isopropyl adduct is added to a solution of 318 mg of a4 dissolved in 3.2 ml of dimethylacetamide, and the mixture is stirred at 50 to 55°C for 8 hours. The reaction solution was treated in the same manner as in Example 1(a) to give dimethyl N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-α-difluoromethylglutamate 5
Get 422mg. Yield 87.9%, melting point 176-177.5℃
(Recrystallized from acetonitrile). Mass spectrum m/z 532 (M + ), 500 (M +
N 2 H 4 ), 134 (CH 3 NHC 6 H 4 CO) 19 FNMR (DMSO−d 6 ) δ (C 6 F 6 ) 33.67~
35.67 (4 linbes, 2F) b 5 331 mg was suspended in 11 ml of ethanol.
Add 2.21ml of 1N sodium hydroxide and bring to room temperature.
Stir for 24 hours and leave in the refrigerator overnight. The deposited precipitate is collected by filtration, dissolved in 5.1 ml of water, and filtered. The filtrate was adjusted to pH 4 with 1N hydrochloric acid, cooled on ice, and the precipitate was collected by filtration to give N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-α-difluoromethyl. Obtain 260 mg of glutamic acid 6 . Yield 80.0%, melting point
205-207℃ (decomposition). Elemental analysis Calculated value (%) as C 21 H 22 O 5 N 8 F 2・1.5H 2 O: C, 47.46; H, 4.74; N, 21.09;
F, 7.15 Experimental value (%): C, 47.43; H, 4.77; N, 21.02;
F, 7.13 19 FNMR (DMSO-d 5 ) δ (C 6 F 6 ) 35.33
(d, 2F, J=56.5Hz) Reference example 1 (Cbz: carbobenzoxy; i-pr: isopropyl) a. Add 24.6 thionyl chloride to a mixture of 7 4 g of γ-fluoroglutamic acid and 100 ml of isopropanol.
ml and heated under reflux for 15 hours. After cooling, the solvent is distilled off from the reaction solution, and isopropanol is added and concentrated to give diisopropyl γ-
6.91 g of fluoroglutamate hydrochloride 8 are obtained.
This is crystallized from ether-petroleum ether,
Further, when recrystallized from acetone-ether,
It forms crystals with a melting point of 140-143℃. 19 FNMR (acetone- d6 )δ( C6F6 ) -28.00
~-25.67 (m, 1F) b 8.82 g of N-carbobenzoxy-N-methyl-4-aminobenzoyl chloride was added to a suspension consisting of 6.91 g of the above 8 and 88 ml of dimethoxyethane, and 8.44 ml of triethylamine was added under ice cooling. was added dropwise and stirred for 2 hours. After the reaction, ethyl acetate is added, and the mixture is washed successively with dilute hydrochloric acid, water, dilute aqueous sodium bicarbonate solution, and water, dried over anhydrous sodium sulfate, and concentrated. The residue is subjected to silica gel chromatography on a Lorber column, eluting with benzene:ethyl acetate (5:1 v/v).
The eluate is concentrated to obtain 11.19 g of diisopropyl N-carbobenzoxy-N-methyl-4-aminobenzoyl-γ-fluoroglutamate 9 . Yield 89.5%, melting point 88-89°C (recrystallized from ether-petroleum ether). 19 FNMR( CDCl3 )δ( C6F6 )−30.00~
27.58 (m, 1F) c Add 26 ml of 30% hydrogen bromide-acetic acid to 5.15 g of the above 9 , and stir at room temperature for 4 hours. Add 260 ml of ether to the reaction solution, and remove the ether solution by decanting when cold. The remaining oil is washed with ether and dissolved in methylene chloride. methylene chloride solution
Washing successively with 1N aqueous potassium bicarbonate solution and water, drying over anhydrous sodium sulfate, and concentrating yielded diisopropyl N-methyl-4-aminobenzoyl-γ-fluoroglutamate 1 as an oil.
Get 3.40g. Yield 89.2%. This was subjected to silica gel chromatography using a Rover column and eluted with benzene:ethyl acetate (3:1 v/v). The eluate was concentrated and the residue was recrystallized from ethyl acetate-petroleum ether, melting point 101~
It becomes a crystal at 104℃. 19 FNMR (acetone- d6 )δ( C6F6 ) -29.00
~-26.17 (m, 1F) Reference example 2 a Dissolve 1.23 g of α-difluoromethylglutamic acid 0.5 hydrate 10 in 35 ml of methanol, -10
℃, add 0.58 ml of trifluoromethanesulfonic acid and 6.07 ml of thionyl chloride,
Heat and stir at 50-60°C overnight. After cooling, the solvent was distilled off from the reaction mixture, methanol was added to the residue, and the mixture was concentrated again to obtain 2.24 g of dimethyl α-difluoromethylglutamate trifluoromethanesulfonate 11 as an oil. 19 FNMR (D 2 O) δ (C 6 F 6 ) 34.47 (dd, 1F,
J FF = 283.9Hz, J HF = 52.9Hz), 39.60 (dd, 1F,
J FF = 283.9 Hz, J HF = 51.3 Hz) 9.06 g of N-carbobenzoxy-N-methyl-4-aminobenzoyl chloride was added to a mixture of 2.24 g of b 11 and 7.4 ml of dimethoxyethane, and then 5.83 g of triethylamine was added under ice cooling. Drop ml. The mixture was stirred for 30 minutes under ice cooling and then brought to room temperature.
Stir for 1.5 hours. The reaction solution was treated in the same manner as in Reference Example 1(b) to obtain dimethyl N-carbobenzoxy-N-methyl-4-aminobenzoyl-α-difluoromethylglutamate 12 as an oil.
Get 1.86g. Mass spectrum m/z 492 (M + ), 448 (M +
C 3 H 8 ), 268 (

【式】),91(C6 H5−CH219FNMR(CDCl3)δ(C6F6)33.00−34.33
(4 lines,2F) c 上記12 276mgと30%臭化水素−酢酸溶液1.5
mlの混合物を室温下に2時間攪拌する。反応液
を参考例1(c)と同様に処理し、油状物としてジ
メチルN−メチル−4−アミノベンゾイル−α
−ジフルオロメチルグルタメ−ト142mgを得
る。収率70.6%。 質量スペクトルm/z 358(M+),327(M+
CH3O),272(M+−C4H6O2),134(CH3NH
−C6H4CO) 19FNMR(アセトン−d6)δ(C6F6)33.88
(dd,1F,JFF=277.3Hz,JHF=56.4Hz),
35.96(dd,1F,JFF=277.3Hz,JHF=56.4Hz)。 なお、上記のα−ジフルオロメチルグルタミン
酸は次のように製造した。 (Phはフエニルを表わす) a ジメチルグルタメート塩酸塩13 11.6g、ベ
ンズアルデヒド5.6ml、およびトリエチルアミ
ン7.7mlの混液を室温下5時間攪拌する。反応
液に塩化メチレンを加え、水洗後、無水芒硝で
乾燥し、溶媒を留去してシツフ塩基1414.4gを
油状物として得る。 IR(CHCl3):2950,2840,1735,1640,1580,
1440,1340〜1140cm-1 b 上記14 5.01gをテトラヒドロフラン10mlに
溶解した溶液を水素化ナトリウム3.8gのテトラ
ヒドロフラン7ml懸濁液に加え、水素の発生が
止まるまで攪拌する。これを室温まで冷却し、
予め、大過剰のジフルオロクロロメタン
(CHClF2)をテトラヒドロフラン30mlに吹き
込んだ溶液に加え、水中に注いだ後、酢酸エチ
ルで抽出する。抽出後を水洗後、無水芒硝で乾
燥し、溶媒を留去して、ジメチル・N−ベンジ
リデン−α−ジフルオロメチルグルタメート15
4.35gを油状物として得る。 19FNMR(CDCl3)δ(C6F6)32.67〜34.33
(4 lines,2F) c 上記15 4.35gに1N塩酸43mlを加え、室温で
2時間攪拌する。減圧下、1H塩酸を留去し、
水を加え、さらに水を減圧留去する。残られる
残渣に濃塩酸50mlを加え12時間加熱還流後、減
圧下、濃塩酸を留去し、水を加え、不溶物を濾
去した後、濃縮する。残渣をイオン交換樹脂
(AG 50W−X8,バイオラド ラボラトリーズ
(Biorad Laboratories))278mlにかけ、水で
流出する。最初に流出する400mlを集め、水を
留去すると5−ジフルオロメチル−2−ピロリ
ドン−5−カルボン酸16 0.80gを得る。16 の物理衡数 融点180−181℃(水から再結晶) 19FNMR(D2O)δ(外部C6F6)32.24(dd,
JFF=279.4Hz,JHF=53.3Hz),39.14(dd,JFF
=279.4Hz,JHF=52.5Hz) さらに水で流出し、酸性部分700mlを集め、水
を留去するとα−ジフルオロメチルグルタミン酸
10′ 0.54gを得る。10′ の物理衡数 融点129−131℃(水から再結晶) 19FNMR(D2O)δ(外部C6F6)34.24(dd,
1F,JFF=279.4Hz,JHF=54.9Hz),39.52(dd,
1F,JFF=279.4Hz,JHF=52.3Hz)
[Formula]), 91 (C 6 H 5 −CH 2 ) 19 FNMR (CDCl 3 ) δ (C 6 F 6 ) 33.00−34.33
(4 lines, 2F) c 276 mg of the above 12 and 1.5 mg of 30% hydrogen bromide-acetic acid solution
ml of the mixture is stirred at room temperature for 2 hours. The reaction solution was treated in the same manner as in Reference Example 1(c), and dimethyl N-methyl-4-aminobenzoyl-α was obtained as an oily product.
-142 mg of difluoromethylglutamate 4 are obtained. Yield 70.6%. Mass spectrum m/z 358 (M + ), 327 (M +
CH 3 O), 272 (M + −C 4 H 6 O 2 ), 134 (CH 3 NH
−C 6 H 4 CO) 19 FNMR (acetone-d 6 ) δ (C 6 F 6 ) 33.88
(dd, 1F, J FF = 277.3Hz, J HF = 56.4Hz),
35.96 (dd, 1F, JFF = 277.3Hz, JHF = 56.4Hz). Note that the above α-difluoromethylglutamic acid was produced as follows. (Ph represents phenyl) a A mixture of 11.6 g of dimethyl glutamate hydrochloride 13 , 5.6 ml of benzaldehyde, and 7.7 ml of triethylamine is stirred at room temperature for 5 hours. Methylene chloride was added to the reaction solution, washed with water, dried over anhydrous sodium sulfate, and the solvent was distilled off to obtain 14.4 g of Schiff's base 14 as an oil. IR ( CHCl3 ): 2950, 2840, 1735, 1640, 1580,
1440, 1340-1140 cm -1 b A solution of 5.01 g of the above 14 dissolved in 10 ml of tetrahydrofuran is added to a suspension of 3.8 g of sodium hydride in 7 ml of tetrahydrofuran, and stirred until hydrogen generation stops. Cool this to room temperature,
A large excess of difluorochloromethane (CHClF 2 ) is added to a solution in which 30 ml of tetrahydrofuran is bubbled in advance, poured into water, and then extracted with ethyl acetate. The extracted product was washed with water, dried over anhydrous sodium sulfate, and the solvent was distilled off to give dimethyl/N-benzylidene-α-difluoromethylglutamate 15
4.35 g are obtained as an oil. 19 FNMR( CDCl3 )δ( C6F6 )32.67 ~ 34.33
(4 lines, 2F) c Add 43 ml of 1N hydrochloric acid to 4.35 g of the above 15 and stir at room temperature for 2 hours. 1H hydrochloric acid was distilled off under reduced pressure.
Water is added and further water is distilled off under reduced pressure. Add 50 ml of concentrated hydrochloric acid to the remaining residue and heat under reflux for 12 hours, then distill off the concentrated hydrochloric acid under reduced pressure, add water, filter off insoluble matter, and concentrate. The residue is applied to 278 ml of ion exchange resin (AG 50W-X8, Biorad Laboratories) and flushed out with water. The first 400 ml flowing out is collected and the water is distilled off to give 0.80 g of 5-difluoromethyl-2-pyrrolidone-5-carboxylic acid. Physical equilibrium number of 16 Melting point 180-181℃ (recrystallized from water) 19 FNMR (D 2 O) δ (external C 6 F 6 ) 32.24 (dd,
J FF = 279.4Hz, J HF = 53.3Hz), 39.14 (dd, J FF
= 279.4 Hz, J HF = 52.5 Hz) Furthermore, 700 ml of the acidic portion was collected and the water was distilled off, resulting in α-difluoromethylglutamic acid.
10′ yields 0.54g. Physical equilibrium number of 10' Melting point 129-131℃ (recrystallized from water) 19 FNMR (D 2 O) δ (external C 6 F 6 ) 34.24 (dd,
1F, J FF = 279.4Hz, J HF = 54.9Hz), 39.52 (dd,
1F, J FF = 279.4Hz, J HF = 52.3Hz)

Claims (1)

【特許請求の範囲】 1 一般式 (式中、R1は水素またはフツ素、R2は水素ま
たはジフルオロメチルをそれぞれ表わすが、R1
とR2が同時に水素である場合を除く。)で示され
る化合物またはその塩。
[Claims] 1. General formula (In the formula, R 1 represents hydrogen or fluorine, and R 2 represents hydrogen or difluoromethyl, respectively .
and R 2 are hydrogen at the same time. ) or its salt.
JP16691184A 1984-08-08 1984-08-08 Fluorine-containing methotrexate derivative Granted JPS6144890A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP16691184A JPS6144890A (en) 1984-08-08 1984-08-08 Fluorine-containing methotrexate derivative

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16691184A JPS6144890A (en) 1984-08-08 1984-08-08 Fluorine-containing methotrexate derivative

Publications (2)

Publication Number Publication Date
JPS6144890A JPS6144890A (en) 1986-03-04
JPH0533230B2 true JPH0533230B2 (en) 1993-05-19

Family

ID=15839924

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16691184A Granted JPS6144890A (en) 1984-08-08 1984-08-08 Fluorine-containing methotrexate derivative

Country Status (1)

Country Link
JP (1) JPS6144890A (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4844986A (en) * 1988-02-16 1989-07-04 Becton, Dickinson And Company Method for preparing lubricated surfaces and product
WO2008125613A1 (en) 2007-04-11 2008-10-23 Merck Eprova Ag 18f-labelled folates
CA2670371C (en) 2007-04-11 2015-01-20 Merck Eprova Ag 18f-labelled folates
SG195545A1 (en) 2008-10-10 2013-12-30 Merck & Cie 18f-labelled folates as pet radiotracers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANN.N.Y.ACAD.SCI=1971 *
J.MED.CHEM=1983 *

Also Published As

Publication number Publication date
JPS6144890A (en) 1986-03-04

Similar Documents

Publication Publication Date Title
JPH0572384B2 (en)
JPH10182583A (en) New hydroxamic acid derivative
JPH0210830B2 (en)
ES2250100T3 (en) DERIVATIVES OF PIRIDAZIN-3-ONA AND DRUGS CONTAINING THESE DERIVATIVES.
JPH0150698B2 (en)
JPH05246980A (en) Beta-oxo-beta-benzenepropanethioamide derivative
JPH0533230B2 (en)
JP2018522068A (en) Anti-tumor compounds targeting IDH2 mutations and methods of use thereof
JPS63165362A (en) Substituted aminomethyl-5, 6, 7, 8- tetrahydronaphthyloxyacetic acids, intermediates, production thereof and their use in medicine
JP3042915B2 (en) 3- (1H-indazol-3-yl) -4-pyridinamine and method for producing the same
JPH07242670A (en) Pyrrolo(3,2-e)pyrazolo(1,5-a)pyrimidine derivative and circulatory disease-treating agent using the same
JPH10139761A (en) Substituted pyridine
JPS6024789B2 (en) 5-Fluorouracil derivative compound
JPS5944312B2 (en) Production method of indazole derivatives
JPS6281385A (en) Novel methotrexate derivative
US2430051A (en) Soluble sulfanilamide derivatives and process of preparing them
WO2019184772A1 (en) Gibberellin-like compound, preparation method thereof, pharmaceutical composition, uses and intermediate thereof
JP2937387B2 (en) Process for producing 5-substituted 2-amino-3-cyanopyrazines
KR800001248B1 (en) Process preparing for 1-alkyl-2-(phenoxymethyl)-5-nitro-imidazoles
JP4055246B2 (en) 5-chloro-6- (α-fluoroalkyl) -4-pyrimidone and process for producing the same
JP3145533B2 (en) New methotrexate derivatives
JPH0717594B2 (en) Novel sulfone anilide derivative
JPH024781A (en) Anilinopyrimidine derivative
JPH0571584B2 (en)
JPS597172A (en) Preparation of guanidine derivative

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term